GSK's Cabenuva maintains continuous viral suppression in 81% of patients in real-world study

• GSK-majority-owned ViiV Healthcare announced five-year US real-world study results supporting Cabenuva’s sustained effectiveness as a long-acting HIV treatment.
• The OPERA study followed 6,955 adults switching from daily oral treatment; most maintained viral suppression and remained on Cabenuva.
• Confirmed treatment failure was uncommon, supporting the injectable regimen’s role as an alternative to daily oral therapy.
• Results will be presented at IDWeek 2026 in Washington, D.C., October 21-24.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. GSK plc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610210901BIZWIRE_USPR_____20261019_BW882869) on October 21, 2026, and is solely responsible for the information contained therein.